/PBM

PBM Stock - Psyence Biomedical Ltd.

Q: What is the analyst price target for PBM?

Analyst price target information is not currently available for PBM.

Q: What is PBM's market cap?

Market capitalization information is not currently available for PBM.

Healthcare|Biotechnology|NASDAQ

$1.00-31.51%

$0.46 (-31.51%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.10

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PBM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.28

52W High$21.20

52W Low$0.97

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A
Gross Profit	$-4,268	$-240	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-3,663,023	$-2,751,825	$-1,293,980	$-334,290
Net Income	$1.01M	$-51,159,048	$8.01M	$8.23M
Net Margin	N/A	N/A	N/A	N/A
EPS	$1.78	$-7.85	$-0.64	$0.25

Company Overview

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Visit Website

Frequently Asked Questions about PBM

What is PBM's current stock price?

Psyence Biomedical Ltd. (PBM) is currently trading at $1.00 per share. The stock has moved -31.51% today.

What is the analyst price target for PBM?

No analyst price targets are currently available for this stock.

What sector is Psyence Biomedical Ltd. in?

Psyence Biomedical Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PBM's market cap?

Psyence Biomedical Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.

Does PBM pay dividends?

No, Psyence Biomedical Ltd. does not currently pay a dividend to shareholders.